药物机械导管导向溶栓治疗急性髂股深静脉血栓的大样本研究
单中心回顾性分析230例急性髂股深静脉血栓患者接受药物机械导管导向溶栓(PMCDT)的结果:解剖成功率达95.2%,Marder评分从术前12.65±2.1降至术后2.4±1.3(P<.01),1年总复发率19.63%,静脉疾病特异性生活质量从基线至12个月平均改善29.41±1.99(P=.029)。
要点
- 230例急性髂股深静脉血栓患者行PMCDT,解剖成功率达95.2%。
- Marder评分从术前12.65±2.1降至术后2.4±1.3(P<.01)。
- 1年总复发率19.63%,12个月PTS严重程度评分较6个月无统计学显著差异。
核心结论
- 对于经过选择的急性髂股深静脉血栓患者,使用PMCDT联合术后抗凝治疗可显著减少血栓负荷、减轻腿部疼痛和肿胀,并在6个月时显著降低PTS严重程度评分。
研究设计与样本
- 单中心回顾性研究,回顾2017年1月至2018年12月期间接受PMCDT治疗急性髂股深静脉血栓的230例患者。
- 分析术前、术中、术后变量、Marder评分、结局以及使用Villalta评分和静脉临床严重程度评分进行的随访评估。
主要发现
- 230例患者中解剖成功率为95.2%。
- 平均Marder评分从术前12.65±2.1降至术后2.4±1.3(P<.01)。
- 早期复发性血栓形成发生于13例患者(5.65%)。
- 1个月、6个月和12个月随访时的一期通畅率分别为94.0%、87.2%和81.7%。
- 从1个月到6个月,Villalta评分从8.32±4.14降至3.43±0.61,静脉临床严重程度评分从4.0±1.8降至1.82±0.36(P<.05);12个月随访时PTS严重程度评分与6个月时相比无统计学显著差异;静脉疾病特异性生活质量从基线至12个月的平均变化为29.41±1.99(P=.029);1年总复发率为19.63%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We have analyzed our single-center immediate and follow-up results in the management of acute iliofemoral deep vein thrombosis (IFDVT) using pharmacomechanical catheter-directed thrombolysis (PMCDT) to determine the safety, accuracy, and effects on quality of life and whether this treatment strategy prevents post-thrombotic syndrome (PTS). METHODS: The cases of 230 patients who had undergone PMCDT to treat IFDVT from January 2017 to December 2018 were retrospectively reviewed. The preoperative, operative, and postoperative variables, Marder scores, outcomes, and follow-up assessments with the Villalta score and venous clinical severity score were investigated. RESULTS: Anatomic success was achieved for 95.2% of the 230 patients. The mean Marder score had decreased from 12.65 ± 2.1 to 2.4 ± 1.3 postoperatively (P < .01). Early recurrent thrombosis had developed in 13 patients (5.65%). The primary patency at the 1-, 6-, and 12-month follow-up visits was 94.0%, 87.2%, and 81.7%, respectively. From 1 to 6 months, the Villalta score had decreased from 8.32 ± 4.14 to 3.43 ± 0.61 and the venous clinical severity score had decreased from 4.0 ± 1.8 to 1.82 ± 0.36 (P < .05). No statistically significant difference was found in the PTS severity scores at 12 months of follow-up compared with at 6 months. The mean change in the venous disease-specific quality of life from baseline to 12 months was 29.41 ± 1.99 (P = .029). The total recurrence rate was 19.63% at 1 year. CONCLUSIONS: For a select group of patients with acute IFDVT, the use of PMCDT and postoperative anticoagulation therapy offered significant reductions in clot burden, leg pain, and swelling, achieving a significant reduction in PTS severity scores at 6 months.
引用
- Budak AB, Gunertem OE, Ozisik K, et al. Pharmacomechanical catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis in a large study population. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34890845. doi:10.1016/j.jvsv.2021.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。